OCM
AKBA icon

Orchard Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Orchard Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.4K Hold
53,510
– – 0.08% 45
2025
Q4 		$86.2K Hold
53,510
– – 0.07% 43
2025
Q3 		$146K Hold
53,510
– – 0.13% 43
2025
Q2 		$195K Hold
53,510
– – 0.22% 36
2025
Q1 		$103K Sell
53,510
-7,200
-12% -$14.7K 0.07% 38
2024
Q4 		$115K Sell
60,710
-24,006
-28% -$41.7K 0.05% 55
2024
Q3 		$112K Sell
84,716
-2,110
-2% -$2.82K 0.04% 55
2024
Q2 		$88.6K Sell
86,826
-21,634
-20% -$26.7K 0.03% 42
2024
Q1 		$198K Buy
108,460
+21,634
+25% +$34.6K 0.06% 47
2023
Q4 		$108K Buy
86,826
+20,000
+30% +$20.4K 0.03% 44
2023
Q3 		$76.2K Hold
66,826
– – 0.03% 42
2023
Q2 		$61.1K Hold
66,826
– – 0.02% 46
2023
Q1 		$37.4K Hold
66,826
– – 0.01% 48
2022
Q4 		$38.6K Sell
66,826
-185,000
-73% -$58K 0.01% 50
2022
Q3 		$80K Hold
251,826
– – 0.03% 46
2022
Q2 		$89K Sell
251,826
-1,510,905
-86% -$634K 0.03% 47
2022
Q1 		$1.26M Buy
1,762,731
+169,200
+11% +$362K 0.36% 36
2021
Q4 		$3.6M Hold
1,593,531
– – 1.06% 29
2021
Q3 		$4.59M Hold
1,593,531
– – 1.38% 29
2021
Q2 		$6.04M Buy
1,593,531
+53,277
+3% +$179K 1.74% 27
2021
Q1 		$5.21M Buy
1,540,254
+683,116
+80% +$2.46M 1.64% 29
2020
Q4 		$2.4M Buy
+857,138
New +$2.5M 1.02% 32

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Orchard Capital Management's AKBA Position: Q1 2026 in Review

Orchard Capital Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 53,510 shares worth $74.4K. The position accounts for 0.08% of the portfolio, ranked #45.

Orchard Capital Management first reported a position in AKBA in Q4 2020 and has held it in 22 quarters since. The position peaked at $6.04M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Orchard Capital Management held 53,510 shares of Akebia Therapeutics worth $74.4K as of Q1 2026.
  • Orchard Capital Management left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up 0.08% of Orchard Capital Management's portfolio in Q1 2026, its #45 holding.
  • Orchard Capital Management first reported a position in Akebia Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Orchard Capital Management's Akebia Therapeutics position peaked at $6.04M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Orchard Capital Management's 13F filing for Q1 2026, filed 13 May 2026.